# Verrica Pharmaceuticals Inc. (VRCA) — capital_raise [announced]
Source: SEC API (secapi.ai) · situation sit_eeed08dedef553fec1ae · retrieved 2026-08-12T06:56:38.804Z

## Overview
Verrica Pharmaceuticals Inc. is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers; its lead product YCANTH (VP-102) is the first and only FDA-approved healthcare professional-administered treatment for molluscum contagiosum.

Verrica Pharmaceuticals Inc. entered into a credit agreement (the "Facility") with an entity controlled by Paul B. Manning, Verrica's Chairman and largest shareholder, for up to $27.5 million. Based on the Company's current operating plan, the full $27.5 million that may be available under the facility could extend the Company's cash runway into 2028, providing non-dilutive capital to support YCANTH's continued commercialization and advance the ongoing Phase 3 common warts program.

## Terms
- Counterparty: Paul B. Manning (entity controlled by) · Deal value: $27.5M · Consideration: cash

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · 8-K (0001193125-26-338273): 8-K - Verrica Pharmaceuticals Inc. — *Verrica Pharmaceuticals Inc. is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers; its lead product YCANTH (VP-102) is the first and only FDA-approved healthcare professional-administered treatment for molluscum contagiosum.* Verrica Pharmaceuticals Inc. entered into a credit agreement (the "Facility") with an entity controlled by Paul B. Manning, Verrica's Chairman and largest shareholder, for up to $27.5 million. Based on the Company's current operating plan, the full $27.5 million that may be available under the facility could extend the Company's cash runway into 2028, providing non-dilutive capital to support YCANTH's continued commercialization and advance the ongoing Phase 3 common warts program.
  https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-338273.txt

## Citations
- 0001193125-26-338273 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526338273